Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 6;68(11):e0092424.
doi: 10.1128/aac.00924-24. Epub 2024 Oct 9.

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

Tania Blanco-Martín #  1 , Inmaculada López-Hernández #  2   3 , Belén Aracil #  3   4 , Lucía González-Pinto  1 , Pablo Aja-Macaya  1 , Isaac Alonso-García  1 , Salud Rodríguez-Pallares  1 , Lucía Sánchez-Peña  1 , Michelle Outeda-García  1 , María Pérez-Vázquez  3   4 , Juan Carlos Vázquez-Ucha  1   3 , Alejandro Beceiro  1   3 , Álvaro Pascual  2   3 , Germán Bou  1   3 , Lorena López-Cerero #  2   3 , Jesús Oteo-Iglesias #  3   4 , Jorge Arca-Suárez #  1   3 ; GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)
Affiliations

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

Tania Blanco-Martín et al. Antimicrob Agents Chemother. .

Abstract

We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by whole-genome sequencing (WGS). The collection covered nine carbapenemase associations: VIM + OXA-48 (21/57), NDM + OXA-48 (11/57), KPC + VIM (10/57), KPC + OXA-48 (6/57), IMP + OXA-48 (3/57), NDM + KPC (2/57), NDM + VIM (2/57), NDM + GES (1/57), and KPC + IMP (1/57). Ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam were the least active options. Aztreonam/avibactam and aztreonam/nacubactam were active against the whole collection and yielded MIC50/MIC90 values of ≤0.25/0.5 mg/L and 1/2 mg/L, respectively. Cefepime/zidebactam (56/57 susceptible), meropenem/xeruborbactam (56/57 susceptible), cefepime/nacubactam (55/57 susceptible), and cefiderocol (53/57 susceptible) were also highly active, with MIC50/MIC90 values ranging from ≤0.25-2 mg/L to 2-4 mg/L, respectively. Meropenem/ANT3310 (MIC50/MIC90 = 0.5/≥64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC50/MIC90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.

Keywords: Enterobacterales; antimicrobial resistance; carbapenemase; cefiderocol; double carbapenemase; β-lactamase; β-lactamase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Merck Sharp & Dohme (MSD) provided relebactam powder, and cefiderocol was provided by Shionoghi. Commercial suppliers did not exercise any control over the conduct or reporting of the research. J.C.V.-U. has received honoraria for lectures and/or presentations from MSD. G.B. has received funding and study materials from MSD, grants contracts from MSD, Pfizer, ABAC Therapeutics, and Roche, and consulting fees and honoraria for lectures and/or presentations from MSD, Shionogi, Pfizer, and Roche. J.A.-S. has received honoraria for lectures and/or presentations from MSD, Shionogi, Pfizer, Roche, and Advanz.

References

    1. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G, et al. . 2019. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 4:1919–1929. doi:10.1038/s41564-019-0492-8 - DOI - PMC - PubMed
    1. Bianco G, Boattini M, Comini S, Casale R, Iannaccone M, Cavallo R, Costa C. 2022. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Eur J Clin Microbiol Infect Dis 41:573–580. doi:10.1007/s10096-022-04408-5 - DOI - PMC - PubMed
    1. Riccobono E, Salvetti S, Coppi M, Montenora I, Di Pilato V, Rossolini GM. 2023. Citrobacter freundii resistant to novel β-lactamase inhibitor combinations and cefiderocol, co-producing class A, B and D carbapenemases encoded by transferable plasmids. J Antimicrob Chemother 78:1677–1682. doi:10.1093/jac/dkad150 - DOI - PubMed
    1. Paterson DL. 2024. Antibacterial agents active against Gram negative bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 33:371–387. doi:10.1080/13543784.2024.2326028 - DOI - PubMed
    1. Huang Y-S, Chen P-Y, Chou P-C, Wang J-T. 2023. In vitro activities and inoculum effects of cefiderocol and aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae. Microbiol Spectr 11:e0056923. doi:10.1128/spectrum.00569-23 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources